MANF2 for treatment of Parkinson's disease

• US 9,127,082 B2
• Filed: 02/26/2008
• Issued: 09/08/2015
• Est. Priority Date: 08/30/2002
• Status: Active Grant

• Current Assignee: Herantis Pharma PLC
• Original Assignee: Herantis Pharma PLC
• Inventors: Saarma, Mart, Lauren, Juha, Lindholm, Paivi, Timmusk, Tonis, Tuominen, Raimo
• Primary Examiner(s): Marvich, Maria
• Application Number:
  US12/037,535
• Publication Number:
  US 20080269154A1
• Time in Patent Office: 2,751 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A01K 2217/075 inducing loss of function, i.e. knock out
• CPC Class Codes: A01K 2227/105 Murine
• CPC Class Codes: A01K 2267/0356 Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 25/30 for treating abuse or dependence
• CPC Class Codes: C07K 14/475 Growth factors; Growth regulators

Abstract

The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes.

Claims

1. A method for treating Parkinson'"'"'s disease in a patient, comprising:

directly administering to the brain of the patient a pharmaceutically effective amount of a pharmaceutical composition comprising an adenoviral, an adeno-associated viral or a lentiviral vector comprising an expression control sequence operably linked to the MANF2 nucleic acid sequence encoding the MANF2 polypeptide of SEQ ID NO;

2 or the mature MANF2 polypeptide consisting of amino acids 27-187 of SEQ ID NO;

2.

2. The method according to claim 1, wherein the vector comprises the MANF2 nucleic acid sequence of SEQ ID NO:

1.